Kymera Therapeutics (KYMR) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Vaxcyte (PCVX) over the past year, gaining 90.4% versus a gain of 59.9%. Over five years, PCVX leads with a +174.3% price change compared with +89.4% for KYMR. Vaxcyte is the larger company by market cap ($9.96 billion vs $8.91 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYMR | PCVX |
|---|---|---|
| Share price | $108.35 | $66.96 |
| Market cap | $8.91B | $9.96B |
| 1-day change | +2.24% | +0.39% |
| YTD return | +39.25% | +45.12% |
| 1-year return | +90.35% | +59.92% |
| 5-year return | +89.42% | +174.31% |
| EPS (TTM) | $-3.25 | $-7.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $39.21M | — |
| Revenue growth (YoY) | -16.70% | — |
| Net income (latest FY) | $-311.35M | $-766.63M |
| Gross margin | 0.00% | — |
| Operating margin | -891.07% | — |
| Net margin | -794.04% | — |
| 52-week high | $130.05 | $90.75 |
| 52-week low | $55.26 | $39.87 |
| Distance from 52-week high | -16.69% | -26.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +28.58% | +65.59% |
| Average volume | 690.98K | 1.50M |
| Shares outstanding | 82.26M | 148.81M |
| Employees | 273 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed PCVX by 30.4 percentage points over the past year.
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
KYMR vs PCVX FAQ
Which is bigger, Kymera Therapeutics or Vaxcyte?
Vaxcyte (PCVX) is larger, with a market capitalization of $9.96B compared with $8.91B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, KYMR or PCVX?
KYMR returned +90.35% over the past 12 months, compared with +59.92% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Kymera Therapeutics and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.